@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix schem: . @prefix go: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix hasAgent: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0042789 . sub:_2 geneProductOf: hgnc:11364; a Protein: . sub:_3 occursIn: obo:CLO_0007599, obo:UBERON_0002048, species:9606; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject schem:Pyridone%206; a rdf:Statement . sub:assertion rdfs:label "a(SCHEM:\"Pyridone 6\") -| tscript(p(HGNC:STAT3))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "We next determined whether the ?EGFR-expressing MCF-10A cells produced high levels of IL-6, leading to activation of STAT3, as was observed in lung adenocarcinoma–derived cell lines harboring mutant EGFR. The ?EGFR–MCF-10A cells were treated with P6, gp130, and IL-6 blocking antibodies, which inhibited STAT3 activation."; prov:wasQuotedFrom pubmed:18060032 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:18060032; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:13.895+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }